Fluorescence-Guided Surgical Resection for Reducing Unexpected Positive Margins in Patients With Sarcoma, SarcoSIGHT Trial

Summary

This phase II trial compares standard of care surgical resection to fluorescence-guided surgical resection using indocyanine green and fluorescence imaging for reducing unexpected positive margin rates in patients with sarcoma. Surgical margins are one of the criteria used in assessing the effectiveness of a given surgical procedure. They are the edges or border of the tissue removed in cancer surgery. A negative margin means that the resected tumor is surrounded by normal tissue, which implies there is no disease left in the patient. By contrast, a positive margin means that sarcoma cells are visible at the edge of the tumor. Positive margins may be classified as planned when they are expected pre-operatively due to the preservation of a critical structure, or unexpected when the pathologist reports the presence of tumor at the margin despite the surgeon having intended to remove it in its entirety. Fluorescence-guided surgery is an established surgical method that involves the administration of fluorescent dye (in this case, indocyanine green) into the tumor, which can then be visualized with a special camera during surgery to help surgeons identify tumor versus healthy tissue. Fluorescence-guided surgery may reduce the rate of unexpected positive margins in patients undergoing surgery for sarcoma.

Eligibility

Inclusion Criteria:

* Documented written informed consent of the participant
* Histologically confirmed diagnosis of intermediate to high grade sarcoma
* All ages
* Amenable to surgical resection as a part of curative intent for the patient
* Willingness to:

  * Respond to surveys during the trial
  * Permit medical record/ clinical laboratory result review

Exclusion Criteria:

* Due for surgery with palliative intent
* Recurrent tumors
* Intracranial, retroperitoneal, and visceral anatomical locations
* A woman of childbearing potential who is currently pregnant (as confirmed by urine pregnancy test)
* A woman who are currently breastfeeding
* Known allergies to ICG, iodine, iodine dyes or shellfish
* Unable to provide written and informed consent
* Patients with hyper-thyroidism or autonomic thyroid adenomas
* Premature infants/neonates with exchange transfusion indication due to hyperbilirubinemia

Conditions3

Interventions1

Locations1 site

Find trials near these locations

Related trials

• Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Giant Cell Tumor of Bone Surgery — Shanghai Jiao Tong University Affiliated Sixth People's Hospital
• Accuracy of Indocyanine Green (ICG) Fluorescence Imaging in Tenosynovial Giant Cell Tumor Surgery — Shanghai Jiao Tong University Affiliated Sixth People's Hospital
• ICG-fluorescence Imaging for Intraoperative Breast Cancer Margins Evaluation: a Dose-timing Study — Jules Bordet Institute
• Implementation of Indocyanine Green to Identify Sentinel Lymph Nodes During Surgery for Breast Cancer — Isabelle Henskens
• Near-Infrared Fluorescence Guided Robotic Pulmonary Segmentectomy for Early Stage Lung Cancer — St. Joseph's Healthcare Hamilton
• Study Evaluating Near-infrared Imaging Coupled With Indocyanine Green for Intraoperative Control of Resection Margins in ENT Surgery — Gustave Roussy, Cancer Campus, Grand Paris
• The Preoperative Administration of ICG Improves Tumor Detection in Patients Undergoing Minimally Invasive Hepatic Resection Guided by Conventional Intraoperative Ultrasound. — Hospital Universitari Vall d'Hebron Research Institute
• A Study Evaluating the Feasibility and Compliance of Manual Lymphatic Drainage Comparing Indocyanine-Green (ICG) Guided vs. Traditional Guided in Patients Undergoing Axillary Node Dissection for the Treatment of Breast Cancer — University of Florida

Browse More Trials